JK06
Asset
Targets 5T4-expressing tumor cells to deliver a cytotoxic drug payload.
- Stage
- Phase 2
- Modality
- Other
- Target
- Not known
- 4
- Indications
- 1
- Trial
- 2
- Developers
Trial NCT06667960 is still running. Named in the news on Oct 23, 2026. businesswire.com
Indications
4Breast cancer
Phase 2, businesswire.com, Oct 23, 2026
Locally advanced or metastatic solid tumors
Phase 2, businesswire.com, Oct 23, 2026
Non-small cell lung cancer
Phase 2, businesswire.com, Oct 23, 2026
1 more
In the full profile
- Owner and partners2
- Trials1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.